Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Posted on by Neuroscientists

Assoc. Prof. Dr. Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Assoc. Prof. Dr. Izabela Małysz-Cymborska,  Department of Neurology and Neurosurgery, School of Medicine, University of Warmia and Mazury, Poland.

Dr. Izabela Małysz-Cymborska is a distinguished biomedical researcher and Associate Professor in Neurosurgery at the University of Warmia and Mazury, Poland. Her academic path began with a Master’s in Biology and culminated in a Ph.D. focused on hormonal mechanisms, followed by a Habilitation in Medicine. Her research spans neuroregeneration, stem cell therapy, and immunomodulatory strategies for neurological diseases such as ALS and stroke. She has led and contributed to nationally funded projects like NanoTech4ALS, Explore Me, and her current OPUS-funded investigation using a swine model for stroke therapy. Her interdisciplinary approach bridges molecular biology, reproductive science, and clinical neuroscience, demonstrating a rare ability to translate foundational research into therapeutic innovation.

Profile

Google Scholar

🎓 Early Academic Pursuits

Dr. Izabela Małysz-Cymborska embarked on her academic journey with a deep-rooted interest in biological sciences. Born on September 21, 1985, in Poland, she pursued her undergraduate studies at the University of Warmia and Mazury in Olsztyn, earning a Master of Science degree in Biology in 2009. Her passion for advanced biomedical research led her to the Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences, where she completed her Ph.D. in 2015. Her doctoral research, grounded in hormonal action mechanisms, laid the foundation for her future contributions to neurobiology and regenerative medicine.

🧠 Professional Endeavors in Neuroscience

Dr. Małysz-Cymborska’s postdoctoral and professional journey has been largely rooted in neuroscientific investigation, with a special focus on neuroregeneration and stroke therapy. Since 2021, she has held the position of Associate Professor in the Department of Neurosurgery at the University of Warmia and Mazury. Her early postdoctoral fellowships (2015–2018) focused on pioneering work in the application of glial progenitors and stem cells in neurological disorders like ALS. These formative experiences not only enriched her research trajectory but also provided a vital bridge between animal studies and translational medicine.

🧪 Research Focus and Scientific Contributions

Dr. Małysz-Cymborska’s research portfolio reflects a consistent dedication to understanding complex neural pathologies and their treatment through regenerative approaches. She has led and contributed to several national and international projects, including NanoTech4ALS, which investigated MRI-monitored transplantation techniques using hydrogel carriers for ALS treatment. Her current role as Principal Investigator in the OPUS-funded project explores an endovascular model of stroke in swine, opening new therapeutic pathways for immunomodulation. She has also delved into reproductive biology, investigating the influence of gonadotropins on prostaglandin synthesis and the function of the corpus luteum, showcasing her multidisciplinary expertise.

🧬 Bridging Regeneration and Technology

A major hallmark of Dr. Małysz-Cymborska’s work is the integration of regenerative medicine and cutting-edge biomedical technologies. Her involvement in Explore Me and NanoTech4ALS demonstrated her commitment to merging cellular therapy with advanced biomaterials and imaging. These projects explored the therapeutic potential of mesenchymal stem cells and human glial progenitors for neurodegenerative conditions, reflecting her drive to push boundaries in translational medicine and neurosurgery.

🏅 Accolades and Recognition

Dr. Małysz-Cymborska’s scientific accomplishments were recognized through her Habilitation Degree in Medicine, awarded in 2022 by the University of Warmia and Mazury—a prestigious academic achievement in Poland that underscores her contributions to the medical sciences. Additionally, her appointment as the Dean’s representative for animal experiments between 2018 and 2019 further illustrates the trust and respect she commands within her institution and the research community.

🌍 Impact and Influence in Translational Neuroscience

Her work has had significant implications not only in Poland but also across the global neuroscience landscape. By focusing on models that simulate real-world human neurological disorders, such as swine models for stroke and ALS, she has established platforms that can more accurately predict treatment outcomes in humans. Her collaborative efforts within national strategic medical programs have enriched the broader field of translational neuroscience, particularly in immune response modulation and neural repair mechanisms.

🔮 Legacy and Future Contributions

As her OPUS project continues until 2025, Dr. Izabela Małysz-Cymborska is poised to deliver crucial insights into stroke immunotherapy. Her legacy lies in her ability to traverse boundaries between endocrinology, neurobiology, and regenerative therapy—crafting a unique niche that advances both fundamental science and clinical application. With a promising trajectory ahead, she is set to influence future protocols in neurovascular therapy, offering hope to patients with currently untreatable conditions.

Publication

  • Hydrogel-based scaffolds to support intrathecal stem cell transplantation as a gateway to the spinal cord: clinical needs, biomaterials, and imaging technologies
    Authors: JM Oliveira, L Carvalho, J Silva-Correia, S Vieira, M Majchrzak, …
    Year: 2018

 

  • Advances in bioinks and in vivo imaging of biomaterials for CNS applications
    Authors: EP Oliveira, I Malysz-Cymborska, D Golubczyk, L Kalkowski, …
    Year: 2019

 

  • The role of glia in canine degenerative myelopathy: relevance to human amyotrophic lateral sclerosis
    Authors: D Golubczyk, I Malysz-Cymborska, L Kalkowski, M Janowski, JR Coates, …
    Year: 2019

 

  • Methacrylated gellan gum and hyaluronic acid hydrogel blends for image-guided neurointerventions
    Authors: S Vieira, P Strymecka, L Stanaszek, J Silva-Correia, K Drela, …
    Year: 2020

 

  • MRI-guided intrathecal transplantation of hydrogel-embedded glial progenitors in large animals
    Authors: I Malysz-Cymborska, D Golubczyk, L Kalkowski, A Burczyk, M Janowski, …
    Year: 2018

 

  • Endovascular model of ischemic stroke in swine guided by real-time MRI
    Authors: D Golubczyk, L Kalkowski, J Kwiatkowska, M Zawadzki, P Holak, J Glodek, …
    Year: 2020

 

  • Expression of the vascular endothelial growth factor receptor system in porcine oviducts after induction of ovulation and superovulation
    Authors: I Małysz-Cymborska, A Andronowska
    Year: 2014

 

  • Rabbit model of human gliomas: implications for intra-arterial drug delivery
    Authors: H Qin, M Janowski, MS Pearl, I Malysz-Cymborska, S Li, CG Eberhart, …
    Year: 2017

 

  • Two in one: use of divalent manganese ions as both cross-linking and MRI contrast agent for intrathecal injection of hydrogel-embedded stem cells
    Authors: L Kalkowski, D Golubczyk, J Kwiatkowska, P Holak, K Milewska, …
    Year: 2021

 

  • Effect of hCG and eCG treatments on Prostaglandins Synthesis in the Porcine Oviduct
    Authors: I Małysz‐Cymborska, AJ Ziecik, A Waclawik, A Andronowska
    Year: 2013

 

🧾 Conclusion

Dr. Małysz-Cymborska’s career reflects a compelling fusion of scientific curiosity, clinical relevance, and academic rigor. With notable achievements in regenerative medicine and translational neuroscience, she continues to shape the future of therapeutic interventions for complex neurological disorders. Her ongoing research promises to pave the way for advanced stroke treatments and immune-based neurotherapies, cementing her role as a key contributor to modern biomedical science.

Joice Margareth de Almeida Rodolpho | Molecular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Mrs. Joice Margareth de Almeida Rodolpho | Molecular Neuroscience | Best Researcher Award

Mrs. Joice Margareth de Almeida Rodolpho, Universidade Federal de São Carlos, Brazil.

Joice Margareth de Almeida Rodolpho is a dedicated Brazilian researcher with a strong foundation in biotechnology, parasitology, immunology, and molecular biology. She earned her Master’s and Ph.D. from the Federal University of São Carlos (UFSCar), where she explored the role of eosinophils as antigen-presenting cells in parasitic infections like Toxocara canis and Schistosoma mansoni. Her work is recognized for integrating experimental immunology with therapeutic innovations, such as the evaluation of natural plant extracts and nanomaterials for infection control. She further specialized in Flow Cytometry and Oncohematology, enhancing her analytical capabilities. With multiple awards and citations, her impactful contributions continue to strengthen Brazil’s standing in parasitological and immunological research.

Profile

Orcid

🎓 Early Academic Pursuits

Joice Margareth de Almeida Rodolpho began her academic journey in Brazil, developing a strong foundation in the life sciences. Her early interest in molecular biology and parasitology led her to pursue advanced studies at the esteemed Universidade Federal de São Carlos (UFSCar). She earned her Master’s degree in Biotechnology between 2009 and 2012, conducting significant research on Toxocara canis, particularly on the phenotypic characterization of eosinophils as antigen-presenting cells. This early work not only revealed her meticulous scientific inquiry but also laid the groundwork for her deeper exploration into immunology.

🧬 Professional Endeavors in Molecular and Evolutionary Genetics

Driven by a passion for understanding immune responses, Joice pursued a Ph.D. in Evolutionary Genetics and Molecular Biology at UFSCar from 2013 to 2017. Her doctoral research focused on the role of eosinophils as antigen-presenting cells both in vitro and ex vivo, offering vital insights into host-parasite interactions and immune regulation. Her work during this period was supported by a prestigious FAPESP scholarship, demonstrating her academic excellence and the relevance of her contributions. Under the mentorship of Professor Fernanda de Freitas Anibal, Joice refined her skills in experimental immunology and cellular biology.

🧪 Contributions and Research Focus in Parasitology and Immunopathology

Joice Rodolpho’s primary research interests lie at the intersection of parasitology, cellular immunology, and experimental pathology. Her studies explore how parasitic infections, such as those caused by Schistosoma mansoni and Toxocara canis, affect immune cell function, especially eosinophils. She has also contributed to investigations into natural plant extracts, like Mentha piperita L., assessing their therapeutic potential in modulating parasitic infections. Moreover, she extended her expertise to the field of nanomaterials, evaluating the cytotoxicity and cell death mechanisms induced by compounds like Ag₂WO₄, thus bridging classical parasitology with emerging biomedical technologies.

🏅 Accolades and Recognition in Scientific Circles

Throughout her career, Joice has received several recognitions that reflect the impact and originality of her research. In 2010, she was honored with a Menção Honrosa (Honorable Mention) for her work on Mentha piperita L. in treating Schistosoma mansoni, earning 2nd place in diagnostics and treatment. She continued to gain academic acclaim with awards at major conferences, including the VI Congresso da Sociedade Paulista de Parasitologia (2012) and the XXII B-MRS Meeting in 2024, highlighting her work on cytotoxic responses and innovative parasitological control methods. In 2024, her project on the parasitological and pathological evaluation of AW-HRL-C for schistosomiasis control was notably recognized by UNIFESP.

🧠 Impact and Influence in Experimental Immunology

Joice’s dedication to experimental immunology and cytometry has allowed her to mentor and influence upcoming researchers, especially in specialized fields such as flow cytometry. Her recent specialization in Immunology and Oncohematology by Flow Cytometry (2021–2022) at IPESSP further enriched her profile, showcasing her commitment to continuous learning and application of advanced technologies in immune profiling. Her ability to merge classical immunopathology with state-of-the-art cytometric tools reflects her versatility and forward-thinking scientific approach.

🌱 Legacy and Future Contributions in Biomedical Science

Poised to make lasting contributions, Joice Margareth de Almeida Rodolpho stands at the forefront of research into host-pathogen interactions, parasitic disease management, and immune cell function modulation. Her unique interdisciplinary approach—integrating molecular biology, natural product pharmacology, and immunological techniques—positions her as a valuable contributor to both academic research and potential therapeutic advancements. She is expected to lead innovative research in the treatment of neglected tropical diseases and immunological disorders, with implications for global health.

🔬 Research Field Relevance and Scientific Identity

As a scholar deeply embedded in the Brazilian scientific ecosystem, Joice’s identity is reflected in her multiple citation forms, indicating her widespread academic collaborations and international visibility. Her expertise bridges evolutionary genetics, biotechnology, cytometry, and immunoparasitology—making her a multifaceted researcher. Her contributions are cited under various names such as “RODOLPHO, JOICE M. A.” and “Joice Margareth de Almeida Rodolpho,” reflecting a robust presence in scholarly literature and ensuring her work continues to guide parasitological and immunological research for years to come.

Publication

  • Title: Biomarkers and Mental Disorders: A Relevance Analysis Using a Random Forest Algorithm
    Authors: Joice M. A. Rodolpho; Krissia F. Godoy; Bruna D. L. Fragelli; Jaqueline Bianchi; et al.
    Year: 2025

 

  • Title: Death Risk Score Model of Hospitalized COVID‐19 Patients: A Cohort Study
    Authors: Gustavo A. Cruz; Thais B. Boteon; Henrique Pott; Joice M. A. Rodolpho; et al.
    Year: 2025

 

  • Title: Synergistic Antifungal Effect and In Vivo Toxicity of a Monoterpene Isoespintanol Obtained from Oxandra xylopioides Diels
    Authors: Orfa I. C. Martínez; Alberto Angulo; Joice Rodolpho; Krissia F. Godoy; et al.
    Year: 2024

 

  • Title: Synergistic Antifungal Effect and In Vivo Toxicity of the Monoterpene Isoespintanol Obtained from Oxandra xylopioides Diels (Preprint)
    Authors: Orfa I. C. Martínez; Alberto Angulo; Joice M. A. Rodolpho; et al.
    Year: 2024

 

  • Title: Carbon Black CB-EDA Nanoparticles in Macrophages: Changes in the Oxidative Stress Pathway and in Apoptosis Signaling
    Authors: Joice M. A. Rodolpho; Krissia F. Godoy; Bruna D. L. Fragelli; et al.
    Year: 2023

 

  • Title: HGPRT and PNP: Recombinant Enzymes from Schistosoma mansoni and Their Role in Immunotherapy during Experimental Murine Schistosomiasis
    Authors: Bruna D. L. Fragelli; Ana C. Fattori; Joice M. A. Rodolpho; et al.
    Year: 2023

 

  • Title: Titanium Dioxide Nanoparticle (TiO2 NP) Induces Toxic Effects on LA-9 Mouse Fibroblast Cell Line
    Authors: Ana C. M. Fattori; Patricia Brassolatti; Joice M. A. Rodolpho; et al.
    Year: 2023

 

  • Title: Analysis of Cytotoxicity and Genotoxicity in a Short-Term Dependent Manner Induced by a New Titanium Dioxide Nanoparticle in Murine Fibroblast Cells
    Authors: Pedrino, M.; Brassolatti, P.; Joice M. A. Rodolpho; et al.
    Year: 2022

 

  • Title: Functionalized Titanium Nanoparticles Induce Oxidative Stress and Cell Death in Human Skin Cells
    Authors: Brassolatti, P.; Joice M. A. Rodolpho; Krissia F. Godoy; et al.
    Year: 2022

 

  • Title: Toxicological Effects of the Mixed Iron Oxide Nanoparticle (Fe₃O₄ NP) on Murine Fibroblasts LA-9
    Authors: Alves Feitosa, K.; Joice M. A. Rodolpho; et al.
    Year: 2022

 

🧾 Conclusion

Joice Rodolpho’s academic journey and scientific contributions reveal a researcher of high caliber, committed to advancing our understanding of host-pathogen dynamics and immune system function. Her work, grounded in rigorous experimentation and innovation, holds promise for developing novel therapies for neglected tropical diseases. With a forward-looking approach and interdisciplinary expertise, she stands out as a key contributor in biomedical science, poised to influence future discoveries in immunopathology and disease control.

Caterina Miro | Cellular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Dr. Caterina Miro | Cellular Neuroscience | Best Researcher Award

Dr. Caterina MIRO,  Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy.

Dr. Caterina Miro is a dedicated and accomplished Italian biomedical researcher specializing in thyroid hormone signaling, molecular oncology, and metabolic reprogramming in cancer and systemic diseases. With a Ph.D. awarded with honors in “Newer Biomedical and Surgical Treatments” and multiple postdoctoral fellowships at the University of Naples “Federico II,” her work consistently bridges the gap between molecular biology and translational medicine. Her research focuses on unraveling the roles of thyroid hormones in tumor progression, chemoresistance, and metabolic dysfunctions, with notable projects funded by premier institutions such as AIRC and Fondazione Veronesi. Dr. Miro has gained recognition for her contributions to endocrine oncology and her growing influence in the academic community.

Profile

Orcid

 

🎓 Early Academic Pursuits

Born on October 23, 1987, in Avellino, Italy, Dr. Caterina Miro’s scientific path began with an early passion for biological sciences. After completing her high school education with distinction (95/100) at the “P.E. Imbriani” Scientific High School, she enrolled at the University of Naples “Federico II,” where she earned both her Bachelor’s and Master’s degrees in Biological Sciences. Her Master’s thesis, which earned a full score of 110/110 cum laude, focused on innovative therapeutic strategies in reactivating tumor suppressor pathways in malignant pleural mesothelioma. Under the mentorship of Prof. Paolo Laccetti and Dr. Francesca Pentimalli, she laid the foundation for a career centered on molecular oncology and translational medicine.

🧪 Professional Endeavors in Biomedical Research

Dr. Miro’s journey into advanced research began with her early involvement in experimental oncology, particularly during her fellowship at the National Cancer Institute “G. Pascale” and IEOS-CNR Naples. From 2015 onwards, she transitioned into focused roles within the Department of Clinical Medicine and Surgery at the University of Naples “Federico II.” Here, she held several key postdoctoral positions, consistently contributing to endocrine oncology and molecular biology research under the guidance of eminent mentors such as Prof. Domenico Salvatore and Prof. Monica Dentice. Her Ph.D. in “Newer Biomedical and Surgical Treatments,” awarded with excellent with honours, further solidified her place in the realm of academic medicine.

🧬 Contributions and Research Focus

The central axis of Dr. Miro’s research revolves around thyroid hormone metabolism and its role in cancer biology and systemic diseases. Her work delves into the genomic and non-genomic effects of thyroid hormones in squamous cell carcinomas, the metabolic reprogramming in obesity, and the interaction between thyroid pathways and muscular dystrophy. Notably, her recent projects funded by prestigious institutions such as AIRC and Fondazione Veronesi address critical questions in the tumor microenvironment, hormone-driven chemoresistance, and endocrine-metabolic cross-talk. Her methodical approach bridges molecular endocrinology with translational cancer therapeutics, paving the way for targeted interventions.

🏅 Accolades and Recognition

Dr. Miro’s academic and research distinction is evident in the highly competitive fellowships and grants she has secured. Among them, the AIRC-funded postdoctoral fellowship (2025–2027) and the Fondazione Veronesi Research Grant (2024–2025) stand out as acknowledgments of her scientific caliber and project innovation. She has consistently earned positions in merit-based fellowships and has been entrusted with executing pivotal roles in nationally and internationally funded research initiatives. Her Ph.D. distinction, cum laude degree, and continued appointments at Italy’s leading medical university further underscore her credibility in the academic and biomedical community.

🧠 Impact and Influence in Molecular Endocrinology

The influence of Dr. Miro’s work extends beyond laboratory findings. By elucidating the stage-specific roles of thyroid hormone in cancer, she has contributed to a better understanding of how endocrine signals shape tumor behavior and progression. Her research also explores new molecular targets for combating chemoresistance and improving therapeutic responses in skin and lung cancers. These contributions not only enrich the scientific literature but also inform clinical strategies and drug development efforts. Her work bridges a crucial gap between metabolic signaling and cancer therapeutics, enhancing the translational potential of endocrine research.

🌍 Legacy and Future Contributions

Looking ahead, Dr. Miro is poised to become a leading voice in the intersection of endocrinology and oncology. Her evolving portfolio—ranging from thyroid hormone function in obesity to Sirtuin-mediated muscular disorders—demonstrates a vision that spans both depth and breadth. As she continues to harness hormone pathways for therapeutic insights, her interdisciplinary collaborations and methodical precision are expected to yield influential results. Her ongoing commitment to mentorship and academic engagement ensures her legacy will extend into nurturing the next generation of biomedical researchers.

🔬 Vision for Integrative Cancer Therapy

At the core of Dr. Miro’s research philosophy is a dedication to integrative approaches in cancer therapy. She envisions a therapeutic landscape where thyroid hormone pathways are not only understood but also manipulated for patient-specific interventions. Her recent investigations into metabolic reprogramming within the tumor microenvironment reflect a shift towards holistic and multi-layered treatment modalities. Through advanced molecular techniques and translational applications, she continues to push the boundaries of how endocrine signals can be decoded and redirected to combat complex diseases like cancer, muscular dystrophy, and systemic metabolic disorders.

Publication

Title: Ursolic Acid-Based Nutraceutical Mitigates Muscle Atrophy and Improves Exercise Performance in Mouse Model of Peripheral Neuropathy
Authors: Caterina Miro, Fortuna Iannuzzo, Lucia Acampora, Annunziata Gaetana Cicatiello, Serena Sagliocchi, Elisabetta Schiano, Annarita Nappi, Federica Restolfer, Mariano Stornaiuolo, Gian Carlo Tenore, et al.
Year: 2025

Title: Leptin enhances the intracellular thyroid hormone activation in skeletal muscle to boost energy balance
Authors: Miro C, Cicatiello AG, Nappi A, Sagliocchi S, Acampora L, Restolfer F, Cuomo O, de Alteris G, Pugliese G, Torabinejad S, et al.
Year: 2025

Title: Muscle PGC‐1α Overexpression Drives Metabolite Secretion Boosting Subcutaneous Adipocyte Browning
Authors: Caterina Miro, Ciro Menale, Lucia Acampora, Annarita Nappi, Serena Sagliocchi, Federica Restolfer, Sepehr Torabinejad, Mariano Stornaiuolo, Monica Dentice, Annunziata Gaetana Cicatiello
Year: 2025

Title: Thyroid Hormone Activation Regulates the Crosstalk between Breast Cancer and Mesenchymal Stem Cells
Authors: Annarita Nappi, Vittoria D’Esposito, Caterina Miro, Alessia Parascandolo, Annunziata Gaetana Cicatiello, Serena Sagliocchi, Lucia Acampora, Sepehr Torabinejad, Federica Restolfer, Maddalena Raia, et al.
Year: 2025

Title: AbaComplex Enhances Mitochondrial Biogenesis and Adipose Tissue Browning: Implications for Obesity and Glucose Regulation
Authors: Serena Sagliocchi, Elisabetta Schiano, Lucia Acampora, Fortuna Iannuzzo, Annunziata Gaetana Cicatiello, Caterina Miro, Annarita Nappi, Federica Restolfer, Mariano Stornaiuolo, Stefano Zarrilli, et al.
Year: 2024

Title: Discovery of Novel Thiazole-Based SIRT2 Inhibitors as Anticancer Agents: Molecular Modeling, Chemical Synthesis and Biological Assays
Authors: Francesco Piacente, Giorgia Guccione, Naomi Scarano, Dario Lunaccio, Caterina Miro, Elena Abbotto, Annalisa Salis, Bruno Tasso, Monica Dentice, Santina Bruzzone, et al.
Year: 2024

Title: Effects of thyroid hormones in skeletal muscle protein turnover
Authors: Annarita Nappi, Caterina Moriello, Maria Morgante, Ferdinando Fusco, Felice Crocetto, Caterina Miro
Year: 2024

Title: Therapeutic Effect of an Ursolic Acid-Based Nutraceutical on Neuronal Regeneration after Sciatic Nerve Injury
Authors: Fortuna Iannuzzo, Annunziata Gaetana Cicatiello, Serena Sagliocchi, Elisabetta Schiano, Annarita Nappi, Caterina Miro, Mariano Stornaiuolo, Adriano Mollica, Gian Carlo Tenore, Monica Dentice, et al.
Year: 2024

Title: Repositioning of Cefuroxime as novel selective inhibitor of the thyroid hormone activating enzyme type 2 deiodinase
Authors: Sagliocchi S, Murolo M, Cicatiello AG, Miro C, Nappi A, Di Cicco E, Torabinejad S, La Civita E, Romano V, Terracciano D, et al.
Year: 2023

Title: SIRT6 pharmacological inhibition delays skin cancer progression in the squamous cell carcinoma
Authors: Elena Abbotto, Caterina Miro, Francesco Piacente, Annalisa Salis, Melania Murolo, Annarita Nappi, Enrico Millo, Eleonora Russo, Elena Cichero, Laura Sturla, et al.
Year: 2023

Conclusion

Dr. Miro’s scientific journey reflects a rare combination of academic excellence, innovation, and translational impact. Through her deep exploration of hormone-driven mechanisms in cancer and other complex diseases, she has significantly advanced our understanding of molecular endocrinology. Her trajectory suggests she is not only a valuable contributor to ongoing biomedical research but also a future leader in the development of integrative therapeutic strategies. With sustained support and collaborative opportunities, Dr. Caterina Miro is poised to make lasting contributions to personalized medicine and targeted cancer therapy in the years ahead.

 

Ivan Zivotic | Molecular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Dr. Ivan Zivotic | Molecular Neuroscience | Best Researcher Award

Dr. Ivan Zivotic, Vinča Institute of Nuclear Sciences, University of Belgrade, Serbia.

Dr. Ivan Životić is a Serbian molecular geneticist whose research focuses on the genetic epidemiology of complex human diseases such as atherosclerosis, congenital kidney anomalies, and chronic inflammatory conditions. With a Ph.D. in Molecular Biology from the University of Belgrade and a master’s background in applied genetics, he has cultivated a strong academic and research foundation. Currently affiliated with the “Vinča” Institute of Nuclear Sciences, he has authored 16 scientific papers and coauthored over 40 abstracts, contributing meaningfully to the fields of genomics and transcriptomics. His expertise lies in deciphering gene-disease associations using modern molecular and computational tools.

Profile

Orcid

🎓 Early Academic Pursuits

Born on July 23, 1986, in Belgrade, Serbia, Dr. Ivan Životić embarked on a promising academic journey rooted in the life sciences. His passion for unraveling the genetic underpinnings of human diseases led him to the Faculty of Biology at the University of Belgrade. He obtained a Master’s degree in Molecular Biology and Physiology in 2011, specializing in applied genetics within the Department of Population Genetics. His master’s thesis explored the role of GST M1 and GST T1 gene deletion polymorphisms in multiple sclerosis, laying the groundwork for his deep engagement in genetic epidemiology. He continued with doctoral studies at the same faculty, where he focused on the molecular biology of eukaryotes. His Ph.D. thesis examined the association between genetic variants on chromosome 9p21 and transcription levels of CDKN2B and HACD4 genes with atherosclerosis and its complications, graduating with an impressive average grade of 9.7.

🧬 Research Focus in Molecular Genetics

Dr. Životić’s research is rooted in molecular genetics with a core focus on the genetic epidemiology of complex human diseases. His scientific curiosity revolves around how genomic and transcriptomic profiles contribute to the development of conditions such as atherosclerosis, congenital kidney anomalies, and chronic inflammatory diseases. His work integrates molecular tools and population studies to understand genetic variants and their influence on disease onset, making valuable contributions to the broader fields of genomics and transcriptomics. His dedication to uncovering genetic risk factors reflects a commitment to improving predictive medicine and tailored healthcare strategies.

🏥 Professional Endeavors in Medical Sciences

Professionally, Dr. Životić holds a distinguished position at the “Vinča” Institute of Nuclear Sciences, a leading Serbian national research institute affiliated with the University of Belgrade. His role within this multidisciplinary environment places him at the forefront of translational research, bridging the gap between laboratory discoveries and clinical applications. Collaborating with esteemed researchers and clinicians, he continually advances the understanding of how molecular mechanisms translate into disease phenotypes, particularly within the realm of cardiovascular and renal health.

📚 Contributions to Scientific Literature

Dr. Životić has authored 16 research papers in internationally recognized SCI journals and coauthored over 40 scientific abstracts presented at prestigious conferences. These publications represent his steady and thoughtful contributions to the academic community. His scholarly output reflects not only the depth of his investigations but also his role in team-based science. His Scopus-indexed h-index of 4 and 54 heterocitations (as of February 12, 2025) demonstrate a growing influence in the field of molecular medical research.

🏆 Accolades and Academic Recognition

Dr. Životić’s academic achievements are complemented by consistent scholarly excellence. With high average grades throughout his university education and a commendable Ph.D. thesis addressing significant clinical concerns, he has earned recognition within his academic circles. His scientific insights into cardiovascular genomics have positioned him as a promising voice among early-career researchers in Serbia’s biomedical community. His educational accomplishments, including supervision under renowned expert Dr. Maja Živković, reflect a foundation built on rigor and mentorship.

🌍 Scientific Impact and Global Relevance

The research conducted by Dr. Životić holds substantial relevance not only within Serbia but also internationally, given the global burden of atherosclerosis and other complex diseases. His work on gene expression, chromosomal variations, and their clinical correlations contributes to a better understanding of disease mechanisms that affect millions worldwide. His interdisciplinary approach, blending genetics, epidemiology, and bioinformatics, is increasingly critical for the development of precision medicine.

🔬 Legacy and Future Contributions

Looking forward, Dr. Životić is poised to make further breakthroughs in the fields of medical genomics and complex disease genetics. As the need for personalized medicine grows, his contributions are expected to inform diagnostic and therapeutic approaches that are tailored to individual genetic backgrounds. With a strong foundation, a collaborative research spirit, and an unwavering focus on human health, Dr. Životić is building a scientific legacy that will inspire future generations of geneticists and medical researchers.

Publication

  • Title: Expression of HMGB1, TGF-β1, BIRC3, ADAM17, CDKN1A, and FTO in Relation to Left Ventricular Remodeling in Patients Six Months after the First Myocardial Infarction: A Prospective Study
    Authors: Jovana Kuveljic, Ana Djordjevic, Ivan Zivotic, Milica Dekleva, Ana Kolakovic, Maja Zivkovic, Aleksandra Stankovic, Tamara Djuric
    Year: 2024

 

  • Title: Gene expression of chemokines CX3CL1 and CXCL16 and their receptors, CX3CR1 and CXCR6, in peripheral blood mononuclear cells of patients with relapsing-remitting multiple sclerosis – a pilot study
    Authors: Ljiljana Stojkovic, Aleksandra Stankovic, Ivan Zivotic, Evica Dincic, Dragan Alavantic, Maja Zivkovic
    Year: 2020

 

  • Title: The Effects of Aronia melanocarpa Juice Consumption on the mRNA Expression Profile in Peripheral Blood Mononuclear Cells in Subjects at Cardiovascular Risk
    Authors: Ljiljana Stojković, Ivan Jovanovic, Manja Zec, Ivan Zivotic, Ivan Zivotić, Jovana Kuveljić, Ana Kolaković, Ivana Kolić, Ana Djordjević, Marija Glibetić et al.
    Year: 2020

 

  • Title: CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI
    Authors: Zivotić I, Djurić T, Stanković A, Milasinovic D, Stankovic G, Dekleva M, Marković Nikolić N, Alavantić D, Zivković M
    Year: 2019

 

  • Title: The HACD4 haplotype as a risk factor for atherosclerosis in males
    Authors: Zivotić I, Djurić T, Stanković A, Ivančević I, Končar I, Milasinovic D, Stankovic G, Alavantić D, Zivković M
    Year: 2018

 

  • Title: 9p21 locus rs10757278 is associated with advanced carotid atherosclerosis in a gender-specific manner
    Authors: Zivotić I, Djurić T, Stanković A, Djordjević A, Končar I, Davidović L, Alavantić D, Zivković M
    Year: 2016

 

  • Title: Genetic Variants in the Vicinity of LGALS-3 Gene and LGALS-3 mRNA Expression in Advanced Carotid Atherosclerosis: An Exploratory Study
    Authors: Djordjevic A, Zivkovic M, Stankovic A, Zivotic I, Koncar I, Davidovic L, Alavantic D, Djuric T
    Year: 2016

 

  • Title: The glutathione S-transferase T1 deletion is associated with susceptibility to multiple sclerosis
    Authors: Živković M, Životić I, Dinčić E, Stojković L, Vojinović S, Stanković A
    Year: 2013

 

✅ Conclusion

Dr. Životić exemplifies a new generation of biomedical scientists committed to bridging genetic science with clinical application. His work not only enhances the understanding of disease pathogenesis but also supports the advancement of personalized medicine. With a growing academic presence, a commitment to collaborative research, and a focus on translational impact, Dr. Životić is well-positioned to make lasting contributions to the global scientific community.

Jun Zhong | Cranial nerve disorders | Best Researcher Award

Posted on by Neuroscientists

Prof. Jun Zhong | Cranial nerve disorders | Best Researcher Award

Prof. Jun Zhong, Xinhua Hospital, Shanghai Jiatong University School of Medicine,  China.

Professor Jun Zhong, born in Shanghai in 1967, is a distinguished neurosurgeon and academic leader affiliated with Shanghai JiaoTong University School of Medicine and XinHua Hospital. His medical education (1996–2000) at Shanghai JiaoTong laid the groundwork for a stellar career marked by both domestic excellence and international exposure, including fellowships in the United States. He is renowned for performing over 14,000 microvascular decompression (MVD) surgeries, offering effective relief for patients with cranial nerve hyperexcitability disorders such as trigeminal neuralgia and hemifacial spasm

Profile

Orcid

 

🎓 Early Academic Pursuits

Born on January 11, 1967, in Shanghai, China, Jun Zhong pursued his medical studies with diligence and ambition. From 1996 to 2000, he completed his medical and doctoral training at Shanghai JiaoTong University, one of China’s most prestigious institutions. This period laid a strong foundation for his lifelong commitment to neurological science and patient care. Dr. Zhong’s early academic journey reflected not only his dedication to the field of neurosurgery but also a deep interest in advancing clinical techniques and research methodologies in neurological disorders.

🧠 Professional Endeavors in Neurosurgery

Professor Zhong currently holds the position of Vice-Chairman in the Department of Neurosurgery at XinHua Hospital, affiliated with Shanghai JiaoTong University School of Medicine. His role as a professor and clinical neurosurgeon demonstrates a perfect blend of academia and practice. He has also enriched his global perspective by working in the United States at institutions like Wayne State University, the University of Michigan in Ann Arbor, and the University of Arkansas in Little Rock. These international fellowships equipped him with world-class surgical skills and innovative clinical approaches that he later introduced in China.

🧬 Contributions and Research Focus

At the forefront of functional neurosurgery, Dr. Zhong has made groundbreaking contributions in the management of cranial nerve hyperexcitability disorders. His expertise is most prominent in microvascular decompression (MVD), a procedure he has performed over 14,000 times—an extraordinary number that speaks volumes about both his proficiency and patient trust. These surgeries have targeted complex conditions such as trigeminal neuralgia, hemifacial spasm, glossopharyngeal neuralgia, and hemimasticatory spasm. Dr. Zhong introduced a “safe & easy” surgical strategy that enhances the safety and effectiveness of MVD, solidifying his reputation as a pioneer in this domain.

🏆 Accolades and Recognition

Dr. Zhong’s innovations have not gone unnoticed in the international medical community. His experimental work on the mechanisms behind cranial nerve hyperexcitability disorders led to the formulation of a novel scientific hypothesis. This work was recognized at the 81st Annual Meeting of the American Association of Neurological Surgeons (AANS) in New Orleans, where he was awarded the International Travel Scholarship—a testament to the global relevance of his research. Such recognition highlights his role as not just a skilled surgeon but a thought leader in neurosurgical research.

📚 Impact through Publications and Medical Consensus

Beyond the operating room, Professor Zhong has been a prolific academic contributor. He has authored and co-authored over 100 scientific papers and has been instrumental in editing four major books focused on functional neurosurgery. His collaborative leadership, particularly alongside Professor Li, was central in drafting the national consensus guidelines for the diagnosis and treatment of trigeminal neuralgia and hemifacial spasm in China. These documents serve as critical references for Chinese neurosurgeons and have standardized care practices across the nation.

🌍 Influence on Global Neurosurgery

Professor Zhong’s blend of Chinese clinical volume and Western surgical training has placed him in a unique position to influence neurosurgery globally. His high-volume surgical experience offers unmatched insights into rare and complex cranial nerve disorders. International scholars and medical institutions continue to engage with his work, learning from the wealth of data and experience his team has generated. His strategies have influenced training modules, surgical workshops, and research designs across Asia and beyond.

🔮 Legacy and Future Contributions

As he continues his journey, Professor Zhong remains a beacon of clinical excellence and scientific inquiry. With a strong academic and surgical legacy already established, his future contributions are expected to expand into mentorship, global collaboration, and the development of minimally invasive neurosurgical techniques. His ongoing efforts aim to improve patient outcomes and make neurosurgical care more accessible, safe, and effective worldwide. By training the next generation of neurosurgeons and continuously refining his methods, he ensures that his impact will resonate for decades to come.

Publication

  • Title: The key to PBC success: Pear or Banana?
    Authors: Yujie Ma, Ge Yao, HaoLin Wang, Zhengnan Huang, Ningning Dou, ZiJian Shi, Jun Zhong, Shiting Li
    Year: 2025

 

  • Title: Revisiting the Efficacy of Redo Microvascular Decompression for Trigeminal Neuralgia
    Authors: Zhongding Zhang, Hua Zhao, Yinda Tang, Baimiao Wang, Qing Yuan, Ying Zhang, Yihua Li, Jun Zhong, Shiting Li
    Year: 2024

 

  • Title: Riveting technique in percutaneous balloon compression for trigeminal neuralgia remedy
    Authors: Haolin Wang, ShaoZhen Hu, Zheng Nan Huang, YuJie Ma, Ge Yao, Kui Chen, Ningning Dou, Lei Xia, Shiting Li, Jun Zhong
    Year: 2024

 

  • Title: Identification of the leverage point in the offending artery
    Author: Jun Zhong
    Year: 2024

 

  • Title: Lumbar Endoscopic Unilateral Laminotomy With Bilateral Decompression Surgery in Severe Lumbar Stenosis Under Electrophysiological Monitoring – Focused on Full-Visualized Trephine/Osteotome
    Authors: Ning-Ning Dou, Hao-lin Wang, Shao-Zhen Hu, Zheng-Nan Huang, Jun Zhong, Shi-Ting Li
    Year: 2023

 

  • Title: Letter to the Editor Regarding “Microvascular Decompression of the Trigeminal Nerve with Petrous Sling Technique: Surgical Video”
    Author: Jun Zhong
    Year: 2020

 

  • Title: A comparative study of intraoperative findings and postoperative outcomes between atypical and typical hemifacial spasms
    Authors: MingXing Liu, Lei Xia, Jun Zhong, Bin Li, NingNing Dou, ShiTing Li
    Year: 2018

 

🧾 Conclusion

Professor Jun Zhong stands as a world-leading figure in the field of functional neurosurgery, particularly in the treatment of cranial nerve disorders. His contributions are marked by a rare combination of high-volume surgical expertise, scientific innovation, and academic leadership. With a legacy built on advancing surgical safety, shaping national protocols, and training future leaders in neurosurgery, he continues to influence the global neurological community. His work not only improves patient outcomes but also propels the field forward with lasting academic and clinical value.

 

Jagadeesh Rao | Neuropharmacology | Best Researcher Award

Posted on by Neuroscientists

Dr. Jagadeesh Rao | Neuropharmacology | Best Researcher Award

Dr. Jagadeesh Rao,  IGC Pharma LLC, United States.

Dr. Jagadeesh S. Rao is a distinguished neuroscientist and clinical researcher with over 15 years of experience in neuroscience, psychiatry, neuropharmacology, and drug development. His career is marked by significant contributions to the understanding and treatment of neurodegenerative diseases, especially Alzheimer’s disease. With a strong academic foundation in molecular biology and biochemistry, Dr. Rao has led groundbreaking work in clinical trial design, preclinical toxicology, and regulatory submissions, including IND and CMC documentation for FDA approvals. He currently serves as Principal Scientist at IGC Pharma Inc., where he leads teams in Phase I and II clinical trials, manages CROs and budgets, and has developed both OTC and investigational drug products.

Profile

Orcid

🧠 Early Academic Pursuits

Dr. Jagadeesh S. Rao began his scientific journey with a deep interest in the complexities of the human brain and molecular biology. From the early stages of his academic training, he demonstrated exceptional dedication to exploring the interplay between neurobiology, biochemistry, and psychiatric health. His pursuit of a Ph.D. laid a robust foundation in neuroscience and neuropharmacology, equipping him with a multidisciplinary understanding of the cellular and molecular mechanisms that underlie neurodegenerative and neuropsychiatric disorders. This strong academic grounding would later become the driving force behind his innovative contributions to research in pain, Alzheimer’s disease, and drug development.

🧪 Professional Endeavors in Neuroscience and Drug Development

With over 15 years of professional experience, Dr. Rao has successfully navigated and led multiple domains including toxicology, psychiatry, and molecular biology. Currently serving as a Principal Scientist at IGC Pharma Inc., he has taken a prominent role in advancing clinical drug development, particularly in designing and executing Phase I and II trials. His expertise extends to critical regulatory processes such as Investigational New Drug (IND) submissions, clinical protocol design, and Chemistry, Manufacturing, and Controls (CMC). He has actively led teams in drug formulation, batch production, validation, and compliance with FDA and ISO standards—demonstrating a blend of scientific acumen and regulatory insight.

🧬 Contributions and Research Focus in Neuropharmacology

Dr. Rao’s research centers on developing therapeutic interventions for neurodegenerative and neuropsychiatric conditions, especially Alzheimer’s disease. His contributions span the full spectrum of drug development: from preclinical toxicology and pharmacokinetics to clinical pharmacodynamics and regulatory documentation. He has designed preclinical studies adhering to GLP standards, involving mutagenesis assays, reproductive and general toxicity assessments, and immunogenicity tests. Moreover, he played a key role in the development of over-the-counter (OTC) pain relief cream products, contributing both to academic research and commercial innovation. His insights into P450 enzyme polymorphisms and their effects on drug metabolism showcase a precision medicine approach to pharmacological care.

🏅 Accolades and Recognition in Clinical Research

While much of Dr. Rao’s work has been behind the scenes of scientific advancement and regulatory excellence, his leadership in preparing CMC documents and overseeing investigational drug submissions has earned him widespread respect among peers. His oversight of departmental budgets and his management of Clinical Research Organizations (CROs) reflect not only scientific brilliance but also strategic and financial stewardship in clinical drug development. The successful initiation of Phase I and II clinical trials under his guidance stands as a testament to his expertise and diligence in the field.

🌍 Impact and Influence in Translational Medicine

Dr. Rao’s work bridges the gap between laboratory research and clinical application. His projects have advanced the translational medicine field by offering therapeutic candidates that move seamlessly from preclinical safety assessments to human trials. His influence is felt not only through the innovative drugs developed under his watch but also in shaping protocols that align with FDA’s stringent regulatory frameworks. His understanding of the molecular intricacies of neuropsychiatric diseases allows him to propose and test interventions that directly respond to the unmet needs of patients and healthcare systems alike.

🔬 Legacy in Scientific Rigor and Innovation

One of Dr. Rao’s enduring legacies lies in his rigorous approach to clinical pharmacology and his commitment to quality and safety in every phase of drug development. His ability to interpret complex PK/PD data, assess drug-drug interactions, and foresee adverse events has significantly shaped safer and more effective drug protocols. He has also contributed to the creation of technical documentation and risk assessments that serve as gold standards in the field, ensuring compliance and reproducibility for future scientists and clinicians.

🚀 Future Contributions and Vision for Neurotherapeutics

Looking ahead, Dr. Rao continues to pave the way in neurotherapeutics with a focused ambition to develop treatments for cognitive and behavioral disorders rooted in neuroinflammation and synaptic dysfunction. His vision includes refining clinical strategies using personalized medicine models and leveraging his expertise in biochemistry and molecular neuropharmacology. As the global demand for effective neurological therapies increases, Dr. Rao’s evolving research and leadership promise to yield transformative solutions that will benefit countless patients worldwide.

Publication

1. Title: Neurobiological alteration in agitation in Alzheimer’s disease and possible interventions
Author(s): Rao, Jagadeesh S.; Tangarife, Maria Alejandra; Mukunda, Ram
Year: 2024

2. Title: Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain
Author(s): Kim, Hyung-Wook; Cheon, Yewon; Modi, Hiren R.; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2012

3. Title: Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients
Author(s): Rao, J. S.; Keleshian, V. L.; Klein, S.; Rapoport, S. I.
Year: 2012

4. Title: Gabapentin’s minimal action on markers of rat brain arachidonic acid metabolism agrees with its inefficacy against bipolar disorder
Author(s): Reese, Edmund A.; Cheon, Yewon; Ramadan, Epolia; Kim, Hyung-Wook; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.; Taha, Ameer Y.
Year: 2012

5. Title: Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder
Author(s): Ramadan, Epolia; Basselin, Mireille; Rao, Jagadeesh S.; Chang, Lisa; Chen, Mei; Ma, Kaizong; Rapoport, Stanley I.
Year: 2012

6. Title: Altered Expression of G-protein subunits and GRKs in Alzheimer’s Disease
Author(s): Reese, Edmund A.; Kim, Hyung-Wook; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2011

7. Title: Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain
Author(s): Cheon, Yewon; Park, Jee-Young; Modi, Hiren R.; Kim, Hyung-Wook; Lee, Ho-Joo; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.
Year: 2011

8. Title: Dietary n-6 PUFA deprivation downregulates arachidonate but upregulates docosahexaenoate metabolizing enzymes in rat brain
Author(s): Kim, Hyung-Wook; Rao, Jagadeesh S.; Rapoport, Stanley I.; Igarashi, Miki
Year: 2011

9. Title: Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer’s Disease Prefrontal Cortex
Author(s): Igarashi, Miki; Ma, Kaizong; Gao, Fei; Kim, Hyung-Wook; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2011

10. Title: Olanzapine Decreases Brain Arachidonic Acid (AA) Metabolism in Rats by Reducing Plasma Availability of AA
Author(s): Cheon, Yewon; Modi, Hiren R.; Park, Jee-Young; Kim, Hyung-Wook; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.
Year: 2011

✅Conclusion

Dr. Rao’s career reflects a powerful blend of scientific innovation, regulatory excellence, and clinical insight. His dedication to developing safe and effective neurological therapeutics has significantly advanced the field of translational medicine. As a leader, mentor, and researcher, his ongoing work continues to influence modern approaches to treating complex brain disorders, setting a high standard for future neuropharmacological research and therapeutic innovation.

Rui-Juan Lv | Epilepsy | Best Researcher Award

Posted on by Neuroscientists

Dr. Rui-Juan Lv | Epilepsy | Best Researcher Award

Dr. Rui-Juan Lv, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China.

Dr. Lv Rui-Juan is a distinguished neurologist and researcher whose academic foundation was built at Zhengzhou University and Peking Union Medical College. Over the past decade, she has advanced through several professional roles at Beijing Tiantan Hospital, ultimately becoming Chief Physician and Associate Professor. Her research is primarily centered on epilepsy, especially temporal lobe epilepsy and autoimmune encephalitis, with a focus on advanced diagnostic techniques like FDG-PET imaging. Dr. Lv has led over 10 significant research projects and published more than 20 SCI-indexed papers, making substantial contributions to clinical neuroscience in China and beyond.

Profile

Orcid

 

🎓 Early Academic Pursuits

Dr. Lv Rui-Juan began her academic journey in clinical medicine at Zhengzhou University, where she earned her Bachelor’s degree between 2000 and 2005. With a solid foundation in medicine, she further pursued a Master’s degree in Neurology from the same university (2005–2007). Her thirst for deeper neurological knowledge led her to Peking Union Medical College, one of China’s top medical institutions, where she completed her Doctorate in Neurology between 2007 and 2010. These academic milestones established a strong groundwork for her future in both clinical practice and neuroscience research.

🏥 Professional Endeavors

Dr. Lv Rui-Juan’s professional path is deeply rooted in one of China’s most prestigious neurology centers—Beijing Tiantan Hospital, Capital Medical University. Since 2010, she has steadily advanced from Physician to Attending Physician, then to Deputy Chief Physician, and finally, as of December 2022, to Chief Physician. Her parallel appointment as Associate Professor since 2021 highlights her dual commitment to patient care and academic instruction. A notable period in her career includes a clinical research fellowship at the Mayo Clinic (2014–2015), which broadened her international clinical exposure and enriched her perspective in neurology.

🧠 Contributions and Research Focus

Dr. Lv’s work primarily revolves around epilepsy, with a particular focus on temporal lobe epilepsy and autoimmune encephalitis. Her expertise in the clinical and basic sciences has allowed her to lead over ten funded research projects, including prestigious grants from the National Natural Science Foundation of China and the Beijing Natural Science Foundation. Her current project investigates the application of semi-quantitative FDG-PET imaging in the early diagnosis of autoimmune encephalitis—a promising step toward improving diagnostic accuracy and therapeutic outcomes in neurology.

🏅 Accolades and Recognition

Although no individual awards or titles were explicitly listed, Dr. Lv’s rapid rise to Chief Physician and her role as Associate Professor speak volumes about her standing in the medical and academic community. Her contributions are well-acknowledged through over 20 SCI-indexed publications, many of which she authored or co-authored as the first or corresponding author. Her scholarly contributions to CNS Neuroscience & Therapeutics reinforce her recognition in the global neuroscience community.

🌐 Impact and Influence

Dr. Lv Rui-Juan’s research contributes significantly to the clinical translation of neuroscience, helping shape the way autoimmune neurological disorders are diagnosed and treated. Her collaborative approach and long-standing affiliation with Capital Medical University’s Department of Neurology position her as a key influencer in the field. Through her clinical, academic, and research roles, she has mentored peers, contributed to institutional growth, and driven forward China’s role in global neurology advancements.

📚 Legacy and Future Contributions

With a strong academic lineage, international clinical training, and significant research output, Dr. Lv Rui-Juan is well-positioned to influence the next generation of neurologists. Her commitment to combining imaging, clinical research, and patient care sets a high standard. As autoimmune and epilepsy-related disorders become more prevalent, her work on early diagnostic tools and personalized treatment strategies will likely leave a lasting legacy in neurological sciences.

🧬 Neuroscience and Innovation

At the heart of Dr. Lv’s contributions lies a commitment to neurological innovation, particularly within the domain of functional brain disorders and imaging-based diagnosis. Her ability to bridge basic science with clinical neurology through technologies like FDG-PET illustrates a forward-thinking approach. Her sustained research in autoimmune mechanisms and epilepsy pathology stands as a beacon of innovation in translational neuroscience and may pave the way for biomarker-based diagnostics in neurology.

Publication

  • Title: Recognition of seizure semiology and semiquantitative FDG‐PET analysis of anti‐LGI1 encephalitis
    Authors: Tao‐Ran Li, Yu‐Di Zhang, Qun Wang, Xiao‐Qiu Shao, Rui‐Juan Lv
    Year: 2021

 

  • Title: Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?
    Authors: Tao-Ran Li, Yu-Di Zhang, Qun Wang, Xiao-Qiu Shao, Zhi-Mei Li, Rui-Juan Lv
    Year: 2020

 

  • Title: Clinical and genetic characteristics of type I sialidosis patients in mainland China
    Authors: Rui‐Juan Lv, Tao‐Ran Li, Yu‐Di Zhang, Xiao‐Qiu Shao, Qun Wang, Li‐Ri Jin
    Year: 2020

 

  • Title: Correlation between tumor necrosis factor alpha mRNA and microRNA-155 expression in rat models and patients with temporal lobe epilepsy
    Authors: Tao-Ran Li, Yan-Jie Jia, Qun Wang, Xiao-Qiu Shao, Ping Zhang, Rui-Juan Lv
    Year: 2018

 

  • Title: The role of the microRNA-146a/complement factor H/interleukin-1β-mediated inflammatory loop circuit in the perpetuate inflammation of chronic temporal lobe epilepsy
    Authors: Tao-Ran Li, Yan-Jie Jia, Chao Ma, Wen-Ying Qiu, Qun Wang, Xiao-Qiu Shao, Rui-Juan Lv
    Year: 2018

 

  • Title: Circular RNA: a new star in neurological diseases
    Author: Rui-Juan Lv
    Year: 2017

 

  • Title: Status epilepticus-related etiology, incidence and mortality: A meta-analysis
    Author: Rui-Juan Lv
    Year: 2017

 

  • Title: Significance of MDR1 gene C3435T polymorphism in predicting childhood refractory epilepsy
    Author: Rui-Juan Lv
    Year: 2017

 

  • Title: Temporal lobe epilepsy with amygdala enlargement: a subtype of temporal lobe epilepsy
    Author: Rui-Juan Lv
    Year: 2014

 

  • Title: Somatosensory reflex seizures in a patient with hypertrophic cranial pachymeningitis
    Author: Rui-Juan Lv
    Year: 2014

 

🧾 Conclusion

Dr. Lv Rui-Juan’s career reflects a well-rounded blend of clinical excellence, academic rigor, and impactful research. Her dedication to improving the early diagnosis and treatment of complex neurological disorders, such as autoimmune encephalitis and epilepsy, highlights her as a key contributor in the field of neuroscience. Her growing influence, both nationally and internationally, positions her as an ideal candidate for honors such as the Best Researcher Award, with a promising future that will likely bring further advancements in neurological science and patient care.

 

Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Dr. Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Dr.  Liliana Elena Weimer, Center For Global Health Istituto Superiore di Sanita’ Rome, Italy.

Dr. Liliana Elena Weimer is a highly accomplished physician and clinical researcher , where she has risen to the prestigious Level II “First Researcher” position. Her professional focus lies in clinical trials for infectious diseases, particularly HIV and Hepatitis C. She has played a critical role in major national and international research efforts, including collaborations with the U.S. Clinical Trials Group and leadership of the large-scale PITER cohort involving 25,000 HCV patients. She is known not only for her scientific contributions but also for her humanitarian efforts during the COVID-19 emergency. Among her recognitions is the 1st Prize at the 2019 International Congress on Hepatitis C in Seville. Throughout her career, she has exemplified scientific integrity, dedication, and service to public health.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born on December 19, 1965, in Buenos Aires to Italian parents, Dr. Liliana Elena Weimer embraced her dual heritage and committed herself to a life in medicine and research. With Italian citizenship and deep academic determination, she laid the groundwork for her career by studying medicine, ultimately finding her professional home in Italy. Her academic path, though not fully detailed, clearly led her toward a focus on clinical medicine and infectious diseases, with her earliest professional roles marking the beginning of a lifelong engagement in public health and biomedical research. Her intellectual dedication and international roots later became an asset in global research collaborations.

🩺 Professional Endeavors

Dr. Weimer’s distinguished career spans over three decades at the Italian National Institute of Health (ISS), beginning in 1985. Starting as a dedicated clinical physician, she ascended to Level III researcher status by 1990 and continued to grow into higher ranks, culminating in her success in the national Art. 15 competition for the Level II “First Researcher” role in 2022, officially backdated to 2021. Throughout her tenure at ISS, she became a central figure within the Global Health Center in Rome. Known for her tireless commitment, she often described her career not simply as a job but as a “mission,” emphasizing both her personal and professional passion for making a difference in human health.

🧪 Contributions and Research Focus

Specializing in clinical trials, Dr. Weimer has coordinated and participated in numerous groundbreaking studies in HIV and Hepatitis C (HCV). Since the early 1990s, she has collaborated closely with renowned figures such as Prof. Giovanni Rossi, Prof. Stefano Vella, and Prof. Gianni Rezza, contributing to some of the most pivotal HIV antiretroviral therapy trials in history. Her research efforts extended to co-leading and organizing both national and international multicenter clinical trials. Notably, she has been at the forefront of the PITER study, a major nationwide cohort that follows 25,000 patients undergoing HCV treatment—one of the most comprehensive initiatives in Italy in the fight against hepatitis.

🌍 Global Collaborations and Humanitarian Engagement

Her impact extends beyond Italy, thanks to her active involvement with the U.S.-based American Clinical Trials Group on HIV studies. These collaborations have enhanced international understanding and treatment of HIV/AIDS. In addition to her clinical and research commitments, Dr. Weimer also devoted herself to frontline service during the COVID-19 pandemic. Volunteering both with the Civil Protection unit and at Bambino Gesù Children’s Hospital, she demonstrated profound humanitarian values. Her presence during a critical time underscored her belief in serving communities not just from behind a lab desk but also on the ground, directly supporting patients and health systems under strain.

🏅 Accolades and Recognition

Dr. Weimer’s work has been acknowledged at both national and international levels. One of the most prominent recognitions she received was the 1st Prize at the International Congress on Hepatitis C held in Seville in November 2019, a testament to her excellence and influence in the field of infectious disease research. Her achievements are not only measured in accolades but also in the tangible difference her work has made in advancing therapy options and clinical management of chronic viral diseases. Her rise within the ISS and the trust placed in her leadership of major research projects further affirm her standing within the scientific community.

💡 Impact and Influence

Over the course of her extensive career, Dr. Weimer has significantly shaped clinical research strategies in Italy, especially regarding chronic viral infections. Her coordination of thousands of patient cases within structured clinical trials has informed policy decisions and improved treatment protocols nationwide. Her presence at the ISS has also influenced future generations of researchers and clinicians, many of whom benefited from her mentorship, leadership, and example of scientific integrity. Through her rigorous methods and patient-focused approach, she has played a key role in Italy’s standing as a leader in global health research, especially in relation to HIV and HCV.

🔬 Legacy and Future Contributions

Looking forward, Dr. Weimer’s contributions will continue to echo through the fields of virology and clinical medicine. Her involvement in the PITER cohort and other studies has laid down essential groundwork for long-term epidemiological surveillance and patient care strategies. With her appointment as First Researcher, she enters a new chapter of leadership, likely to drive more innovative, patient-centered research initiatives in global health. Her legacy lies not only in her publications or awards but also in the thousands of lives improved by the treatments she helped to test, refine, and implement. The combination of scientific rigor and heartfelt service defines her enduring contribution to modern medicine.

Publication

  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C – TR Morgan, MG Ghany, HY Kim, KK Snow, ML Shiffman, JL De Santo, … – 2010

 

  • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients – SL George, BR Bacon, EM Brunt, KL Mihindukulasuriya, J Hoffmann, … – 2009

 

  • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis – V Saxena, L Nyberg, M Pauly, A Dasgupta, A Nyberg, B Piasecki, … – 2015

 

  • Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy – D Persaud, SC Ray, J Kajdas, A Ahonkhai, GK Siberry, K Ferguson, … – 2007

 

  • Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study – EB Tapper, BR Bacon, MP Curry, DT Dieterich, SL Flamm, LE Guest, … – 2016

 

  • Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with< 50 copies/ml HIV-1 RNA – S Baroncelli, CM Galluzzo, MF Pirillo, MG Mancini, LE Weimer, … – 2009

 

  • Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study – R Mellado-Artigas, LE Mujica, ML Ruiz, BL Ferreyro, F Angriman, E Arruti, … – 2021

 

  • A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients – M Floridia, R Bucciardini, D Ricciardulli, V Fragola, MF Pirillo, LE Weimer, … – 1999

 

  • Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort – LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, … – 2017

 

  • Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER network – LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti, A Gori, A Soria, … – 2017

 

🏁 Conclusion

Dr. Weimer stands as a distinguished figure in the field of global health research, with deep expertise in clinical trials and infectious diseases. Her legacy is marked by landmark contributions to HIV and HCV treatment protocols, influential collaborations, and compassionate public service. Her ongoing work continues to shape public health policy and medical research in Italy and beyond. As she advances in her leadership role at the ISS, her experience, insight, and dedication will remain vital to future innovations in clinical research and global health.

Şenay Yılmaz | Epigenetics | Best Researcher Award

Posted on by Neuroscientists

Prof. Dr. Senay Yılmaz | Epigenetics | Best Researcher Award

Prof. Dr. Senay Yılmaz, Gaziantep University, Turkey.

Prof. Dr. Şenay YILMAZ is a distinguished academic at Gaziantep University, with a strong background in biology, medical genetics, and nutrition. Her academic path—from a BSc in Biology to a PhD in Medical Biology and Genetics—highlights her early and sustained interest in molecular science. Her doctoral work on microRNA expressions in Alzheimer’s patients marked the beginning of her deep research into neurodegeneration.

Profile

Google Scholar

🎓 Early Academic Pursuits

Prof. Dr. Şenay YILMAZ began her academic journey with a strong foundation in biological sciences, earning her BSc in Biology from Mersin University in 1998. Her early curiosity in the molecular world led her to pursue an MSc in Medical Biology at Gaziantep University, where she investigated innovative DNA amplification techniques using random oligonucleotide primers. This work laid the groundwork for her future specialization in medical genetics. Her academic commitment further culminated in a PhD in Medical Biology and Genetics at Mersin University. Her doctoral thesis explored the intricate roles of microRNA expressions and pathway gene polymorphisms in Alzheimer’s disease—signaling her transition into the intersection of neurogenetics and molecular biology.

🧪 Professional Endeavors

Dr. YILMAZ has held successive academic ranks within Gaziantep University’s Faculty of Health Sciences, where she currently serves as a Professor in the Department of Nutrition and Dietetics. Since joining the department in 2014, she has also been its Head, providing strategic leadership and mentoring for nearly a decade. Her dual affiliation with the Medical Biology and Genetics Department underlines her interdisciplinary influence across nutrition, genetics, and molecular medicine. Her professional journey has been characterized by a deep engagement with both teaching and research, integrating molecular science into the realm of health and disease management.

🧬 Contributions and Research Focus

Prof. YILMAZ’s research bridges the complex terrains of molecular genetics, neurodegeneration, and nutritional science. Her scientific focus is marked by the study of epigenetic regulation, particularly microRNAs, in diseases such as Alzheimer’s, epilepsy, and obesity. She has a keen interest in nutrigenomics, investigating how phytochemicals like thymoquinone and cucurbitacins can modulate cellular pathways involved in neurodegenerative disorders. Her work also explores telomere biology and oxidative stress as biomarkers, shedding light on how cellular aging intersects with disease pathology. An emerging area of her research addresses the impact of electromagnetic fields on gene expression, particularly concerning miRNA alterations—a highly relevant and novel dimension in today’s technology-driven world.

🏆 Accolades and Recognition

Although specific awards are not detailed, Prof. Dr. Şenay YILMAZ’s ascent to full professorship and her appointment as department head reflect peer recognition of her scholarly excellence and leadership. Her sustained academic service and progression through ranks signify both institutional trust and a consistent record of academic contribution. Through her publications, theses, and departmental development initiatives, she has earned a respected place within Turkey’s academic and scientific landscape.

🌍 Impact and Influence

The influence of Prof. YILMAZ’s work extends across clinical and academic disciplines. Her research on Alzheimer’s biomarkers and dietary interventions contributes to evolving therapeutic approaches in neurodegenerative care. By integrating molecular biology with nutritional strategies, she advances translational science aimed at public health benefits. She is also shaping academic policy and curriculum within Gaziantep University, nurturing future scientists and dietitians through a curriculum informed by cutting-edge science. Her cross-disciplinary work ensures that molecular insight reaches beyond laboratories into public health frameworks and clinical nutrition.

🔬 Legacy and Future Contributions

Prof. YILMAZ is poised to leave a legacy as a pioneer in molecular nutrition and neurogenetics in Turkey. Her continued focus on emerging research areas like electromagnetic field effects and non-coding RNA biology positions her at the frontier of biomedical innovation. She is expected to contribute to further biomarker discovery, especially as precision nutrition and personalized medicine become integral to healthcare. Her mentorship will likely influence the next generation of molecular biologists and nutritionists, fostering research that bridges basic science with human health solutions.

🧠 Championing Neuro-Molecular Health

At the heart of Prof. Dr. Şenay YILMAZ’s academic identity lies a relentless commitment to decoding the molecular underpinnings of neurological and metabolic diseases. Whether through investigating microRNAs in Alzheimer’s disease or examining dietary phytochemicals as modulators of gene expression, her work consistently centers on improving brain and systemic health. Her integration of nutritional science with molecular biology addresses one of the most urgent challenges of modern medicine: developing non-invasive, diet-based interventions that can prevent or mitigate complex chronic diseases. She stands as a champion for a future where nutrition and genetics jointly optimize human health.

Publication

  • Title: Effects of 2.4 GHz radiofrequency radiation emitted from Wi-Fi equipment on microRNA expression in brain tissue
    Authors: S. Dasdag, M.Z. Akdag, M.E. Erdal, N. Erdal, O.I. Ay, M.E. Ay, S.G. Yilmaz, …
    Year: 2015

 

  • Title: Can peripheral MicroRNA expression data serve as epigenomic (upstream) biomarkers of Alzheimer’s disease?
    Authors: Ş.G. Yılmaz, M.E. Erdal, A.A. Özge, M.A. Sungur
    Year: 2016

 

  • Title: Evaluation of several micro RNA (miRNA) levels in children and adolescents with attention deficit hyperactivity disorder
    Authors: H. Kandemir, M.E. Erdal, S. Selek, Ö.I. Ay, İ.F. Karababa, S.B. Kandemir, M.E. Ay, …
    Year: 2014

 

  • Title: Long term and excessive use of 900 MHz radiofrequency radiation alter microRNA expression in brain
    Authors: S. Dasdag, M.Z. Akdag, M.E. Erdal, N. Erdal, O.I. Ay, M.E. Ay, S.G. Yilmaz, …
    Year: 2015

 

  • Title: Personalized medicine beyond genomics: alternative futures in big data—proteomics, environtome and the social proteome
    Authors: V. Özdemir, E.S. Dove, U.K. Gürsoy, S. Şardaş, A. Yıldırım, Ş.G. Yılmaz, …
    Year: 2017

 

  • Title: The catechol-O-methyl transferase Val158Met polymorphism and susceptibility to cannabis dependence
    Authors: A.B.B. Isir, S. Oguzkan, M. Nacak, S. Gorucu, H.E. Dulger, A. Arslan
    Year: 2008

 

  • Title: Hypothesis: Do miRNAs Targeting the Leucine-Rich Repeat Kinase 2 Gene (LRRK2) Influence Parkinson’s Disease Susceptibility?
    Authors: Ş.G. Yılmaz, S. Geyik, A.M. Neyal, N.D. Soko, H. Bozkurt, C. Dandara
    Year: 2016

 

  • Title: Association of microRNA biogenesis pathway gene variants and alcohol dependence risk
    Authors: H. Gedik, M.E. Erdal, S.G. Yilmaz, C. Sengul, C.B. Sengul, H. Herken
    Year: 2015

 

  • Title: Microribonucleic acid dysregulations in children and adolescents with obsessive–compulsive disorder
    Authors: H. Kandemir, M.E. Erdal, S. Selek, Ö. İzci Ay, İ.F. Karababa, M.E. Ay, …
    Year: 2015

 

  • Title: Effects of Huperzin-A on the Beta-amyloid accumulation in the brain and skeletal muscle cells of a rat model for Alzheimer’s disease
    Authors: C.H. Turkseven, B. Buyukakilli, E. Balli, D. Yetkin, M.E. Erdal, S.G. Yilmaz, …
    Year: 2017

 

🏅 Conclusion

In conclusion, Prof. Dr. Şenay YILMAZ demonstrates the hallmarks of a leading researcher—scientific rigor, interdisciplinary innovation, and societal relevance. Her contributions to molecular neurobiology and nutritional genetics are both deep and impactful. With her sustained academic excellence, leadership roles, and commitment to translational science, she is highly suitable and deserving of the Best Researcher Award. With continued focus on global engagement, her influence in the international scientific community is poised to grow even further.

 

Rosario Osta | Molecular and Cellular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Prof.Dr. Rosario Osta | Molecular and Cellular Neuroscience | Best Researcher Award

Prof. Dr. Rosario Osta, CIBERNED-Fundación Instituto de Investigación Sanitaria de Aragón-Universidad de Zaragoza,  Spain.

Prof. Rosario Osta Pinzolas is a distinguished geneticist and full professor at the University of Zaragoza, Spain. Her academic roots in veterinary sciences and a Ph.D. in Genetics laid the foundation for a prolific career in biomedical research, particularly in the fields of neuroscience and genetic disorders. With leadership roles in multiple high-profile research consortia such as CIBERNED, TRICALS, and ENCALS, she has established herself as a central figure in neurodegenerative disease research. Her scholarly output includes over 100 indexed publications, multiple national and international research projects, and an h-index exceeding 45.

Profile

Orcid 

Scopus

 

🎓 Early Academic Pursuits

Rosario Osta Pinzolas began her academic journey with a solid foundation in veterinary sciences, graduating as Licenciada en Veterinaria from the University of Zaragoza in 1989. Her academic inclinations quickly shifted toward molecular genetics, leading her to complete a Ph.D. in Genetics at the same university in 1994. Her early studies were driven by a deep curiosity about the mechanisms of heredity and gene expression, setting the tone for a lifelong commitment to biomedical research. These formative years cultivated her scientific rigor and sowed the seeds for a career that would eventually bridge basic science and translational medicine.

🧬 Professional Endeavors in Genetics and Biomedicine

Prof. Osta currently holds the esteemed title of Catedrática (Full Professor) in the Department of Anatomy, Embryology, and Genetics at the Faculty of Veterinary Medicine, University of Zaragoza. Since 2018, she has led her department with a focus on integrative biomedical sciences. She is the principal investigator of the LAGENBIO group recognized by both the Aragon Health Research Institute and the Government of Aragon. Under her leadership, the group has developed two major subprograms: TERAGEN and REGENERAGEN. As coordinator of the “Neuroscience and Mental Health Program” at IISA, she has spearheaded numerous efforts to understand and address neurological diseases through genetic approaches.

🧠 Contributions and Research Focus in Neuroscience

A prominent figure in neuroscience, Prof. Osta’s research lies at the intersection of genetics and neurodegeneration. She is currently the principal investigator of the only Aragon-based group within CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), reflecting her national influence. Her team represents Zaragoza in prominent European consortia such as TRICALS and ENCALS, both focused on amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Through more than 100 indexed publications, predominantly in top-tier journals, her work delves into the molecular underpinnings of neurological disorders and explores regenerative medicine strategies, thereby contributing to innovative therapeutic avenues.

🧪 Accolades and Recognition in Scientific Excellence

Prof. Osta’s academic and research career has been punctuated by consistent recognition. She has completed five research productivity periods and one technology transfer period, acknowledged by CNEAI — a mark of sustained scientific impact. She has led over 74 research projects and contributed to more than 100 collaboration contracts, earning her four competitive research awards from respected institutions including CORIS, AREA, IIS, and SEBBM. Her contributions have been lauded not only for scientific quality but also for practical relevance in biomedical advancements.

🚀 Innovation and Impact in Translational Research

An ardent advocate for science with societal impact, Prof. Osta has significantly contributed to technology transfer. She holds nine patents, five of which have been licensed to industry partners. Her collaborations with companies have led to meaningful translational outputs, emphasizing her role in bridging the gap between academic research and real-world solutions. As former Director of the Technology Transfer and Innovation Secretariat at the University of Zaragoza for nearly a decade, she played a crucial role in institutional innovation strategies. Her involvement in joint university-company chairs and her role in the UZ Technology-Based Business Creation Committee for over 12 years further underscore her influence on academic entrepreneurship.

📚 Mentorship and Educational Leadership

Beyond the lab, Prof. Osta has left a profound mark as an educator and mentor. Since 2013, she has coordinated the Interuniversity Doctoral Program in Biomedical and Biotechnological Sciences, a joint initiative between the Universities of Zaragoza and La Rioja. Her mentorship includes the supervision of 13 Ph.D. theses — 9 of which earned international distinction and 6 received extraordinary doctoral awards. Her influence extends to guiding numerous undergraduate and master’s theses, fostering a new generation of scientists with a deep commitment to research excellence and innovation.

🌍 Legacy and Future Contributions

Prof. Rosario Osta’s legacy is defined by her ability to integrate scientific discovery, mentorship, and innovation. As a member of the Scientific Committee of the Luzón Foundation, her vision reaches beyond academia into public health advocacy and strategic research planning. With nearly 19,000 citations on Google Scholar and an h-index of 45, her work continues to inspire and inform global research communities. Her continued leadership in collaborative European projects ensures her contributions will shape the future of neuroscience, genetics, and translational medicine for years to come.

Publication

Title: Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice
Authors: L. Moreno-Martinez, N. Gaja-Capdevila, L. Mosqueira-Martín, R. Osta, F.J. Gil-Bea
Year: 2025

Title: Identifying Hub Genes and miRNAs Associated with Alzheimer’s Disease: A Bioinformatics Pathway to Novel Therapeutic Strategies
Authors: E. Gascón, A.C. Calvo, N. Molina, P. Zaragoza, R. Osta
Year: 2024

Title: Comparative Blood Profiling Based on ATR-FTIR Spectroscopy and Chemometrics for Differential Diagnosis of Patients with Amyotrophic Lateral Sclerosis—Pilot Study
Authors: K. Tkachenko, J.M. González Sáiz, A.C. Calvo, R. Osta, C. Pizarro Millán
Year: 2024

Title: Sex differences on constitutive long non-coding RNA expression: Modulatory effect of estradiol and testosterone in muscle cells
Authors: T. López-Royo, L. Moreno-Martinez, L. Moreno-García, R. Manzano, R. Osta
Year: 2024

Title: Differentially expressed lncRNAs in SOD1 G93A mice skeletal muscle: H19, Myhas and Neat1 as potential biomarkers in amyotrophic lateral sclerosis
Authors: T. López-Royo, L. Moreno-Martinez, P. Zaragoza, R. Manzano, R. Osta
Year: 2024

Title: Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia
Authors: P. Aparicio, D. Navarrete-Villanueva, A. Gómez-Cabello, R. Osta, R. Manzano
Year: 2024

Title: Sporadic Amyotrophic Lateral Sclerosis Skeletal Muscle Transcriptome Analysis: A Comprehensive Examination of Differentially Expressed Genes
Authors: E. Gascón, P. Zaragoza, A.C. Calvo, R. Osta
Year: 2024

Title: Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population
Authors: D. Borrego-Hernández, J.F. Vázquez-Costa, R. Domínguez Rubio, M. Povedano, A. García-Redondo
Year: 2024

Title: New Insights into Endogenous Retrovirus-K Transcripts in Amyotrophic Lateral Sclerosis
Authors: L. Moreno-Martinez, S. Macías-Redondo, M.H.P. Strunk, R. Osta, J. Schoorlemmer
Year: 2024

Title: Analysis of Plasma-Derived Exosomal MicroRNAs as Potential Biomarkers for Canine Idiopathic Epilepsy
Authors: M. García-Gracia, L. Moreno-Martinez, A. Hernaiz, S. García-Belenguer, I. Martín-Burriel
Year: 2024

🏆 Conclusion

Based on her outstanding research contributions, innovation in translational science, mentorship record, and leadership within national and European research programs, Prof. Rosario Osta Pinzolas is an exceptionally strong candidate for the Best Researcher Award. Her profile reflects not only academic excellence but also societal impact and visionary leadership. While there is room for enhanced global outreach, her sustained achievements and contributions make her highly deserving of this prestigious recognition.